MDWD News and Press, MediWound Ltd. From 03/16/23

2023-03-16 14:30:04 ET MediWound Ltd. (MDWD) Q4 2022 Earnings Conference Call March 16, 2023, 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors, IR Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call ...

2023-03-16 07:30:19 ET MediWound ( NASDAQ: MDWD ) appointed Ms. Hani Luxenburg as its new CFO, effective May 14, 2023, replacing Mr. Boaz Gur-Lavie, who served in the role for last year years. Mr. Gur-Lavie will remain with the company through...

2023-03-16 07:14:27 ET MediWound press release ( NASDAQ: MDWD ): Q4 EPS of -$1.18 may not be comparable to consensus of -$0.55. The increase in loss was due to non-cash financial expenses, primarily due to the warrant's revaluation from the September and October 2022 finan...

2022 total revenues of $26.5 million FDA approval of NexoBrid ® in December 2022 ; U.S. commercial availability expected in the second quarter of 2023 EscharEx ® Phase III protocol design is under review by the FDA; study to be initi...

2023-03-15 13:25:55 ET MediWound ( NASDAQ: MDWD ) is scheduled to announce Q4 earnings results on Thursday, March 16th, before market open. The consensus EPS Estimate is -$0.55 (-266.7% Y/Y) and the consensus Revenue Estimate is $6.6M (+20.2% Y/Y). Over the last 1 year...

Appoints Barry Wolfenson, as Executive Vice President of Strategy and Corporate Development Appoints Alicia Torrenova, as Vice President of European Operations Both b ring extensive leadership experience and expertise in wound care and r egene...

YAVNE, Israel, March 02, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth ...

YAVNE, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced management will present at two upcomin...

YAVNE, Israel, Feb. 07, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the closing of its previously announced registered direct offer...

YAVNE, Israel, Feb. 03, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a definitive ...